BNET Industries
Market Cap:$149.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
News & Analysis
Filter by
john maas and pfizer inc. - All News and Analysis
Pharma Roundup: Roche Insulates Against Suitors, Bristol Faces Problems, and More
BNET
- 2009-01-28
Roche's founding family moves to block acquisitions -- In today's feverish climate of M&A speculation, the descendants of Roche's founder indefinitely extended their majority voting stake in the company. This will make it more difficult for a competitor, like Novartis (which already owns 33 percent of Roche), to swoop in...
Pharma Roundup: Pfizer, Wyeth, Amgen, Bristol, and More
BNET
- 2009-01-27
Pfizer and Wyeth: how many jobs are actually being cut? -- The Health Blog provides a run-down on the various figures that are being tossed around, from 18,000 to 26,000. Their estimate with the math to back it up is 19,425 from the combined company, with at least 8,190 coming...
Pharma Roundup: Pfizer and Wyeth, Best Coverage
BNET
- 2009-01-26
Today's big pharma news is, of course, that Pfizer is buying Wyeth a story broken by the Wall Street Journal last week for $60 billion. The deal has seen a flurry of analysis and commentary from the blogosphere; today's Roundup highlights the best content out there. First,...
Pharma Roundup: Pfizer and Wyeth, GlaxoSmithKline Overseas, and More
BNET
- 2009-01-23
Pfizer and Wyeth: ramifications for the industry -- In a much-reported bit of news, Pfizer and Wyeth have been in merger talks for month, although there's no reason to believe the deal will necessarily go through. BNET's Jim Edwards has the details on what that would mean for the two...
Pharma Roundup: Pfizer and the Rat, Johnson & Johnson in Europe, and More
BNET
- 2009-01-22
Pfizer's gruesome new anti-counterfeit campaign -- In the U.K., Pfizer has rolled out a new TV ad that warns consumers against the dangers of counterfeit drugs. The nauseating image of a man pulling a rat from his mouth intends to educate consumers about the dangerous substances like rat poison which...
Pharma Roundup: Pfizer Examined; Merck, UPS, and Wholesalers; and More
BNET
- 2009-01-20
Pfizer's dangerous tendency to save management instead of its operations -- ... is one of the company's problems, according to some commentary in this analysis of the Biggest Pharma. Yes, it is the largest, but that certainly doesn't immunize Pfizer against the tremendous pressures of the current climate -- especially...
Pharma Roundup: Lilly's Zyprexa Settlement; Cuts at Pfizer, Roche; and More
BNET
- 2009-01-15
Lilly's Zyprexa settlment is biggest ever; Pfizer may cut 2,400; Roche cuts 780; Novartis' Ebeling on the future of pharma. by John Maas
Pharma Roundup: Pfizer Sells Experimental Drugs, Genentech Tight-Lipped on Roche, and More
BNET
- 2009-01-14
Pfizer pawns off irrelevant drugs -- Pfizer just sold rights to over 100 experimental drugs. The closeout comes on the heels of the company's autumn promise to streamline R&D; the ditched treatments focus on conditions Pfizer will no longer study, like obesity and high cholesterol. [Source: WSJ Health Blog] ...
Pharma Roundup: Pfizer's Lipitor Patent, Wyeth and Crucell, and More
BNET
- 2009-01-07
Court re-validates Pfizer's Lipitor patent; Wyeth wants to buy Crucell; new spin-off Facet cuts jobs; Merckle family to sell Ratiopharm. by John Maas
Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
BNET
- 2009-01-05
Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
